PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-8.00%
Negative ROE while AGEN stands at 426.61%. Joel Greenblatt would investigate capital misallocation or uncompetitive positioning.
-7.60%
Negative ROA while AGEN stands at 40.80%. John Neff would check for structural inefficiencies or mispriced assets.
-8.06%
Negative ROCE while AGEN is at 65.23%. Joel Greenblatt would look for capital misallocation or cyclical downturn.
100.00%
Gross margin 1.25-1.5x AGEN's 82.70%. Bruce Berkowitz would confirm if this advantage is sustainable.
-2776.39%
Negative operating margin while AGEN has 74.14%. Joel Greenblatt would demand urgent improvements in cost or revenue.
-2756.65%
Negative net margin while AGEN has 70.59%. Joel Greenblatt would check if uncompetitive pricing or bloated costs cause losses.